News for Terumo Corporation (4543.T)

IceCure Medical (ICCM) highlighted its progress in breast cancer treatment at the recent 33rd Annual Meeting of the Japanese Breast Cancer Society in Tokyo. Pro

IceCure Medical's ProSense® achieves 99.02% breast cancer recurrence-free rate in a long-term study. Independent studies on ProSense® presented at the Jap

PR NewswireNASHVILLE, Tenn., July 14, 2025 Real-World U.S. Physician Preference Data1 Demonstrates the SOFIAâ„¢ 88 Catheter's Trackability, Atraumatic Desi

PR NewswireSOMERSET, N.J., July 9, 2025 ”“ VitalStream wearable delivers real-time, beat-by-beat insights to help clinicians detect cardiovascular changes

TEL AVIV, Israel, June 18, 2025 /PRNewswire/ -- MedHub-AI, a global leader in AI-powered cardiovascular diagnostics, announced today that the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan has approved AutocathFFR®, the company's non-invasive, AI-driven software solution for evaluating coronary physiology.

PR NewswireSOMERSET, N.J., May 27, 2025 ”“ Innovative, dual-layer micromesh, closed-cell stent with the flexibility of an open-cell stent for maximizing c

Explore Terumo's steady growth, strong market leadership, and disciplined expansion. A reliable med-tech investment with long-term potential.

Terumo Corporation (OTCPK:TRUMF) Q4 2025 Results Conference Call May 14, 2025 4:00 AM ETCompany ParticipantsJin Hagimoto - Chief Financial OfficerHikaru...

PR NewswireALISO VIEJO, Calif., May 13, 2025 Terumo Neuro's SOFIA â„¢ Catheter Line is Backed By 10 Years of Proven Clinical Performance and Innovation ”“

\n\nPR NewswireLAKEWOOD, Colo., April 16, 2025\n\n\n\nDaly, a 30-year veteran of the healthcare industry, is the latest leadership addition to help Terumo BCT unite b

\n Patrick Daly appointed as Chief Business Officer at Terumo Blood and Cell Technologies (Terumo BCT). Daly brings over 30 years of experience in the heal

Daly, a 30-year veteran of the healthcare industry, is the latest leadership addition to help Terumo BCT unite business areas and fuel enterprise growth

\n Terumo Health Outcomes launches FDA-cleared Medis QFR 3.0 software in the U.S. for coronary physiology assessment. The software is integrated with THO's

Operator: Good morning and thank you for standing by. Currently, all the participants are in a listen-only mode. After management's discussion, there will be a question and answer session.

PR NewswireALISO VIEJO, Calif., March 19, 2025 More than 25,000 Devices Implanted Worldwide from 2010-20251ALISO VIEJO, Calif., March 19, 2025 /PRNewswire/

PR NewswireCAESAREA, Israel, March 10, 2025 Independent study published in Gland Surgery and conducted at Kameda Medical Center in Japan by ProSense® user

Terumo Corporation (OTCPK:TRUMF) Q3 2025 Earnings Conference Call February 13, 2025 3:00 AM ETCompany ParticipantsJin Hagimoto – Chief Financial...

The following slide deck was published by Terumo Corporation in conjunction with their 2025 Q3 earnings call.

IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense ® Sales for 2024 in North America